Biodexa Pharmaceuticals Plc ADR (BDRX) Stock Price, Quote & News

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 29 2048 0180

Website: www.biodexapharma.com

Address:

1 Caspian Point, Caspian Way, Cardiff, United Kingdom

flufever Sep. 1 at 2:30 PM

$BDRX mtpism

0 · Reply

Darkswede Aug. 31 at 3:53 PM

$BDRX when was this stock ever up? Heading for a reverse split again.

0 · Reply

zsk78 Aug. 31 at 3:49 PM

$BDRX see that Roger Maris on the bid, will be watching 0.60-0.61 if we get there

1 · Reply

flufever Aug. 31 at 10:35 AM

$BDRX stay away

0 · Reply

flufever Aug. 29 at 3:40 AM

$BDRX another scam. Always down.

0 · Reply

Mackie2020 Aug. 28 at 5:46 PM

$BDRX I see old gridsters talking a lot about 3s. Here’s some 3s and multiples. Last 5 years performance on BDRX. Anyone hold and manage to survive averaging down?

1 · Reply

The_Gambl3r Aug. 28 at 1:35 PM

$BDRX Someone say Lindros 222

0 · Reply

Bullfrogg Aug. 28 at 11:06 AM

$BDRX 88888888

1 · Reply

Masterson83 Aug. 27 at 5:51 PM

$BDRX Is there a bottom or is this just going to trickle down? The history of this stock is quite disappointing.

0 · Reply

Bullfrogg Aug. 27 at 3:09 PM

$BDRX

0 · Reply

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

Aug 19, 2026, 8:30 AM EDT - 13 days ago

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Jul 30, 2026, 8:00 AM EDT - 4 weeks ago

Biodexa Pharmaceuticals Registration statement: Registration filing

Jul 29, 2026, 4:30 PM EDT - 4 weeks ago

Result of General Meeting

Jul 29, 2026, 8:30 AM EDT - 4 weeks ago

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

Jul 15, 2026, 8:00 AM EDT - 6 weeks ago

Biodexa Pharmaceuticals Registration statement: Registration filing

Jun 30, 2026, 4:30 PM EDT - 2 months ago

Result of Annual General Meeting

2026-06-30T12:21:15.000Z - 2 months ago

Biodexa Pharmaceuticals announces pricing of $3.5M registered offering

Jun 30, 2026, 8:00 AM EDT - 2 months ago

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

2026-06-29T13:15:56.000Z - 2 months ago

Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial

Jun 29, 2026, 8:30 AM EDT - 2 months ago

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Jun 17, 2026, 4:30 PM EDT - 2 months ago

Postponement and Re-scheduling of Annual General Meeting

May 14, 2026, 8:30 AM EDT - 3 months ago

Biodexa issues letter to Shareholders

2026-04-02T23:50:17.000Z - 5 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

2026-04-02T13:12:12.000Z - 5 months ago

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

Apr 2, 2026, 8:30 AM EDT - 5 months ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

2026-03-31T12:47:27.000Z - 5 months ago

Biodexa, Tanner Pharma launch global early access program for FAP patients

Mar 27, 2026, 5:00 PM EDT - 5 months ago

Preliminary Results for the Year Ended 31 December 2025

2026-03-23T14:45:08.000Z - 5 months ago

Biodexa Pharmaceuticals management to meet with Maxim

Mar 23, 2026, 8:30 AM EDT - 5 months ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

2026-03-18T21:10:28.000Z - 5 months ago

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

Mar 18, 2026, 5:00 PM EDT - 5 months ago

ADR Ratio Change

2026-03-09T12:40:09.000Z - 6 months ago

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

Mar 9, 2026, 8:30 AM EDT - 6 months ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Feb 19, 2026, 7:30 AM EST - 6 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

2026-02-04T13:36:46.000Z - 7 months ago

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

Feb 4, 2026, 8:30 AM EST - 7 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

2026-01-05T13:41:08.000Z - 8 months ago

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

Jan 5, 2026, 8:30 AM EST - 8 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

2025-12-18T13:35:26.000Z - 9 months ago

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

Dec 18, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Pricing of $10 Million Public Offering

2025-12-08T14:41:04.000Z - 9 months ago

Biodexa Pharmaceuticals PLC-ADR trading resumes

2025-12-08T14:35:30.000Z - 9 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

2025-12-01T13:35:58.000Z - 9 months ago

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

Dec 1, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

2025-11-24T13:45:58.000Z - 10 months ago

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

Nov 24, 2025, 8:30 AM EST - 10 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

2025-11-17T22:05:23.000Z - 10 months ago

Biodexa Pharmaceuticals files to sell 3.38M units

2025-11-03T13:35:20.000Z - 10 months ago

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

Nov 3, 2025, 8:30 AM EST - 10 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Sep 12, 2025, 8:30 AM EDT - 1 year ago

Interim results for the six months ended June 30, 2025

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 31, 2025, 9:30 AM EDT - 1 year ago

ADR Ratio Change Effective

Jul 28, 2025, 7:00 AM EDT - 1 year ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

flufever Sep. 1 at 2:30 PM

$BDRX mtpism

0 · Reply

Darkswede Aug. 31 at 3:53 PM

$BDRX when was this stock ever up? Heading for a reverse split again.

0 · Reply

zsk78 Aug. 31 at 3:49 PM

$BDRX see that Roger Maris on the bid, will be watching 0.60-0.61 if we get there

1 · Reply

flufever Aug. 31 at 10:35 AM

$BDRX stay away

0 · Reply

flufever Aug. 29 at 3:40 AM

$BDRX another scam. Always down.

0 · Reply

Mackie2020 Aug. 28 at 5:46 PM

$BDRX I see old gridsters talking a lot about 3s. Here’s some 3s and multiples. Last 5 years performance on BDRX. Anyone hold and manage to survive averaging down?

1 · Reply

The_Gambl3r Aug. 28 at 1:35 PM

$BDRX Someone say Lindros 222

0 · Reply

Bullfrogg Aug. 28 at 11:06 AM

$BDRX 88888888

1 · Reply

Masterson83 Aug. 27 at 5:51 PM

$BDRX Is there a bottom or is this just going to trickle down? The history of this stock is quite disappointing.

0 · Reply

Bullfrogg Aug. 27 at 3:09 PM

$BDRX

0 · Reply

luckyluke17 Aug. 27 at 2:38 PM

$BDRX my name is Sidney Crosby

0 · Reply

The_Gambl3r Aug. 27 at 1:02 PM

$BDRX $NUWE $JAGX

1 · Reply

flufever Aug. 26 at 3:40 PM

$BDRX scam

0 · Reply

Lehameri Aug. 26 at 3:16 PM

$BDRX come on man. Like come on. How is this okay?

2 · Reply

zsk78 Aug. 26 at 2:24 PM

$BDRX following my rules and not buying the falling knife hitting new lows, still long hold for now but it’s hard not adding tbh. eRAPA in phase 3 with $7B+ addressable FAP market plus no competition and 3 others in the pipeline in early trials for 6 different indications.. need a biotech catalyst and shift into this market for some momentum

1 · Reply

luckyluke17 Aug. 26 at 1:04 PM

$BDRX just 10% of the all available ADRs borrowed today alone

0 · Reply

luckyluke17 Aug. 26 at 11:38 AM

$BDRX

0 · Reply

Dizzy8 Aug. 26 at 3:48 AM

$BDRX Worth a look

0 · Reply

kennycuda Aug. 25 at 11:49 PM

$BDRX Holy smokes, this is going to reverse split again….. soon the float will be 1k🤦🏻‍♂️

0 · Reply

luckyluke17 Aug. 25 at 11:04 PM

$BDRX also look at that volume compared to any other day.

0 · Reply

luckyluke17 Aug. 25 at 11:04 PM

$BDRX traded the float 15x over today

0 · Reply

zsk78 Aug. 25 at 8:17 PM

$BDRX not a great candle but let it go lower

0 · Reply

Market Cap	893,000.00
Revenue (ttm)	0.00
Net Income (ttm)	-8.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	111,700
Avg Vol	590,698
Day's Range	N/A - N/A
Shares Out	1.03M
Stochastic %K	4%
Beta	1.23
Analysts	Strong Buy
Price Target	$10.00